Scilex Holding Company announced a merger agreement with Denali Capital Acquisition Corp. to combine their businesses, with Semnur Pharmaceuticals, Inc. becoming a wholly owned subsidiary of Denali, valued at $2.5 billion, expected to close in Q1 2025.